Novavax

Valuation Analysis

About the Company

Novavax en bref

Novavax (NVAX) is currently trading at 6,35 € with a market capitalization of 1,0 Md €. The 52-week range spans from 5,38 € to 10,38 €; the current price is 38.8% below the yearly high. Year-over-year revenue growth stands at -79.1%.

💰 Dividende

Novavax currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent Novavax (NVAX) au consensus : None. L'objectif de cours moyen est de 12,23 €, soit un potentiel de +92.81% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 6,07 € à 21,68 €.

Novavax : la thèse d'investissement en détail

Novavax (NVAX) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Revenue is contracting at -79.1% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 2.43, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves.

Valorisation en contexte

The PEG ratio at 1.32 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 92.81% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (26.82%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Novavax?

Compare top-rated brokers — low fees, trusted providers, fully regulated.